Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis of Long-term Clinical Trial Safety Data in Patients with Rheumatoid Arthritis

Sponsorship Statement: This continuing medical education activity is co-sponsored by  and .

Release Date: January 22, 2014
Termination Date: January 21, 2015
This enduring material is approved for 1 year from the date of original release.

Financial Acknowledgement: This activity is supported by independent educational grants from  and  .

Target Audience: The intended audience for the initiative is rheumatologists and other healthcare professionals involved in the treatment of patients with rheumatologic disorders.

Learning Objectives: At the conclusion of this activity participants should be able to:

• Discuss possible adverse events associated with tocilizumab therapy.

Faculty:
Mark Genovese, MD
Professor, Department of Medicine (Immunology & Rheumatology)
Stanford School of Medicine
Palo Alto, California

Accreditation:
Albert Einstein College of Medicine of Yeshiva University is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:
Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the learning objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete and return the registration form and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 1 out of 1 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Albert Einstein College of Medicine of Yeshiva University will issue a Certificate for  AMA PRA Category 1 Credit(s)™.

Einstein Peer Reviewer:
Chaim Putterman, MD
Professor, Department of Medicine (Rheumatology)
Professor, Department of Microbiology & Immunology
Albert Einstein College of Medicine of Yeshiva University
Chief, Division of Rheumatology, Department of Medicine
Montefiore Medical Center
Bronx, New York

Disclosures:
The “Conflict of Interest Statement” of Albert Einstein College of Medicine of Yeshiva University requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

Albert Einstein College of Medicine of Yeshiva University also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device not yet approved for use in the United States.

The staff of CCME of Albert Einstein College of Medicine of Yeshiva University have no conflicts of interest with commercial interests related directly or indirectly to this educational activity.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Faculty members report the following relationship(s):

Mark Genovese, MD
Consultant: Genentech; Roche
Grant/Research: Genentech; Roche

Einstein Peer Reviewer reports the following relationship(s):
Chaim Putterman, MD
No relevant financial relationships to disclose.

 

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.